Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Vemurafenib Plus FOLFIRI in BRAF V600E CRC
NCT03727763Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib and KL-140 in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Objective Response Rate up to 55 months. Status: unknown.
02
Drugs
vemurafenibKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03727763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727763.